



Antibiotice



Explanatory material regarding the item 2.b. of the Notice of the Extraordinary General Meeting of Shareholders dated 29/30.04.2026

2.b. Increase of the Investment Credit Ceiling for a 10 year-term, with an amount of 8,370,000 Euro, with the sum of 58,630,000 Euro up to the value of 67,000,000 Euro, the establishment of guarantees in favor of Transilvania Bank SA, namely a movable mortgage over present and future receivables, as well as over the balances of current accounts and sub-accounts opened by SC ANTIBIOTICE SA with Transilvania Bank SA to be registered with the National Registry for Movable Property Publicity (RNPM); and the appointment of Mr. Ioan NANI , in his capacity as General Director of Antibiotice SA, to negotiate/agree and sign the credit documentation (the credit agreement, security agreements, as well as any other necessary applications, forms or declarations). Accordingly, all financing documents signed/to be signed by the authorized person for the implementation of this resolution shall be assumed by SC Antibiotice SA.

The investment program for the development and consolidation of the company during 2026-2029, in value of 130 million Euro, requires financing worth 58 million Euro, representing the payments for the objectives from the 2026-2027 Investment Plan.

The main investment projects:

- Production, package and storage capacity for sterile products, injectables and topicals;
- INOVA a+ Research & Development Center and production of critical medicines.

Added to these are investments in digitalization and the consolidation investments necessary to maintain quality standards in equipment, workspaces, and transportation and exploitation infrastructure for electricity and drinking water.

We requested the offer from the financing banks we currently collaborate with (Transilvania Bank and UniCredit Bank) and from BRD Groupe Societe Generale, in the following conditions: the loan value: 67,000,000 Euro, without real estate guarantees (with a movable mortgage on the Antibiotice S.A accounts), for a 10-year contractual period, including a 2-year grace period.

The eligibility criteria are:

- the lowest cost over the entire credit period;
- without real estate guarantees.

Taking into consideration:

- the most advantageous interest rate;
- the lowest award fee;
- the requested guarantees: movable mortgage on the Antibiotice S.A accounts

the Transilvania Bank's offer is considered the most advantageous.



Antibiotice



From the amount of the Investment Credit Ceiling of 67,000,000 Euro, currently, following the approval given by the Management Board on 27.02.2026, a financing agreement has been concluded for the amount of 8,370,000 Euro, with payments needing to be made for the project "Production, package and storage capacity for sterile products, injectables and topicals", with a maturity date at the end of March, 2026.

In the Extraordinary General Meeting of Shareholders dated 29.04.2026, an approval will be requested to supplement this Investment Credit Ceiling with the amount of 58,630,000 Euro. Economic and financial indicators confirm a balanced financial structure, respecting safety thresholds regarding liquidity, solvency and debt level - its level increases to an acceptable level for a company that makes increased investments in production infrastructure in a short period of time.

General Director,
Nani Ioan, Economist

Financial Director,
Coman Paula, Economist